Kindred Biosciences (KIN) 3.45 $KIN
Kindred Biosciences Announces HITS Sponsorship
PR Newswire - Wed May 25, 3:05PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series. The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of Weight Loss in Cats
PR Newswire - Mon May 16, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management of weight loss in cats.
KIN: 3.45 (-0.23)
Kindred Bio reports 1Q loss
Automated Insights - Thu May 05, 7:56AM CDT
BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $6.1 million in its first quarter.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs.
KIN: 3.45 (-0.23)
Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA
PR Newswire - Wed May 04, 3:02PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010.
KIN: 3.45 (-0.23)
Kindred Biosciences to Announce First Quarter 2016 Financial Results
PR Newswire - Mon Apr 25, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
KIN: 3.45 (-0.23)
Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors
PR Newswire - Fri Apr 15, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company's Board of Directors. Mr. Montgomery will serve as the Chairman of the Company's Audit Committee.
KIN: 3.45 (-0.23)
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
CRMD: 2.22 (-0.10), MESO: 7.07 (+0.16), KIN: 3.45 (-0.23)
4 Best Biotech Stocks of the First Quarter of 2016
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 9:03AM CDT
Don't miss these best biotech stocks of the first quarter of 2016.
CRMD: 2.22 (-0.10), MESO: 7.07 (+0.16), GILD: 84.45 (-1.32), SHPG: 177.10 (-6.85), AMGN: 154.78 (-2.00), BXLT: 46.02 (-0.18), KIN: 3.45 (-0.23)
Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA
PR Newswire - Tue Mar 15, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta(TM) (dipyrone injection, KIND-012). This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results
PR Newswire - Wed Mar 02, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015.
KIN: 3.45 (-0.23)
Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats
PR Newswire - Tue Jan 26, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.
KIN: 3.45 (-0.23)
Kindred Biosciences to Provide Corporate Update
PR Newswire - Thu Jan 07, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.
KIN: 3.45 (-0.23)
Kindred Biosciences submits NADA's CMC to US FDA for KIND-012
M2 - Fri Dec 18, 5:12AM CST
Biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) said on Thursday that it has submitted the Chemistry, Manufacturing and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012 to the US FDA.
KIN: 3.45 (-0.23)
A Look Inside the Chart, Technical Insights - Research on Westbury Bancorp, FalconStor Software, Kindred Biosciences and Connecture
ACCESSWIRE - Thu Dec 03, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Westbury Bancorp Inc. (NASDAQ: WBB), FalconStor Software Inc. (NASDAQ: FALC), Kindred Biosciences Inc. (NASDAQ: KIN) and Connecture Inc. (NASDAQ: CNXR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CNXR: 1.72 (+0.53), FALC: 1.35 (unch), WBB: 19.79 (-0.02), KIN: 3.45 (-0.23)
Kindred Biosciences Announces HITS Sponsorship
PR Newswire - Wed May 25, 3:05PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series. The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend through both the HITS Ocala Winter Circuit in Ocala, Florida, and the HITS Desert Circuit in Thermal, California.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of Weight Loss in Cats
PR Newswire - Mon May 16, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management of weight loss in cats.
KIN: 3.45 (-0.23)
Kindred Bio reports 1Q loss
Automated Insights - Thu May 05, 7:56AM CDT
BURLINGAME, Calif. (AP) _ Kindred Biosciences Inc. (KIN) on Thursday reported a loss of $6.1 million in its first quarter.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces First Quarter 2016 Financial Results
PR Newswire - Thu May 05, 7:30AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2016 and provided updates on its programs.
KIN: 3.45 (-0.23)
Kindred Biosciences Submits KIND-010 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA
PR Newswire - Wed May 04, 3:02PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010.
KIN: 3.45 (-0.23)
Kindred Biosciences to Announce First Quarter 2016 Financial Results
PR Newswire - Mon Apr 25, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2016 financial results on May 5, 2016 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.
KIN: 3.45 (-0.23)
Kindred Biosciences Elects Herbert D. Montgomery to Join Its Board of Directors
PR Newswire - Fri Apr 15, 8:02AM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company's Board of Directors. Mr. Montgomery will serve as the Chairman of the Company's Audit Committee.
KIN: 3.45 (-0.23)
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
CRMD: 2.22 (-0.10), MESO: 7.07 (+0.16), KIN: 3.45 (-0.23)
4 Best Biotech Stocks of the First Quarter of 2016
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 9:03AM CDT
Don't miss these best biotech stocks of the first quarter of 2016.
CRMD: 2.22 (-0.10), MESO: 7.07 (+0.16), GILD: 84.45 (-1.32), SHPG: 177.10 (-6.85), AMGN: 154.78 (-2.00), BXLT: 46.02 (-0.18), KIN: 3.45 (-0.23)
Kindred Biosciences Submits Final Major New Animal Drug Application Technical Section for Safety for Zimeta to FDA
PR Newswire - Tue Mar 15, 3:01PM CDT
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Safety technical section of the New Animal Drug Application (NADA) for Zimeta(TM) (dipyrone injection, KIND-012). This is the final major technical section to be submitted for Zimeta. The Chemistry, Manufacturing, and Controls technical section was submitted in December 2015 and the Effectiveness technical section was submitted in February 2016.
KIN: 3.45 (-0.23)
Kindred Biosciences Announces Fourth Quarter and Year-End 2015 Financial Results
PR Newswire - Wed Mar 02, 3:01PM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2015.
KIN: 3.45 (-0.23)
Kindred Biosciences Releases Positive Results of Pilot Field Study of KIND-010 for the Management of Weight in Cats
PR Newswire - Tue Jan 26, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today released positive results from its pilot field study (KB104P) of KIND-010 for the management of weight in cats. It also announced successful completion of the sample size reassessment of the ongoing pivotal study.
KIN: 3.45 (-0.23)
Kindred Biosciences to Provide Corporate Update
PR Newswire - Thu Jan 07, 8:02AM CST
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.
KIN: 3.45 (-0.23)
Kindred Biosciences submits NADA's CMC to US FDA for KIND-012
M2 - Fri Dec 18, 5:12AM CST
Biopharmaceutical company Kindred Biosciences (NasdaqCM:KIN) said on Thursday that it has submitted the Chemistry, Manufacturing and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012 to the US FDA.
KIN: 3.45 (-0.23)
A Look Inside the Chart, Technical Insights - Research on Westbury Bancorp, FalconStor Software, Kindred Biosciences and Connecture
ACCESSWIRE - Thu Dec 03, 8:02AM CST
NEW YORK, NY / ACCESSWIRE / December 3, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Westbury Bancorp Inc. (NASDAQ: WBB), FalconStor Software Inc. (NASDAQ: FALC), Kindred Biosciences Inc. (NASDAQ: KIN) and Connecture Inc. (NASDAQ: CNXR). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
CNXR: 1.72 (+0.53), FALC: 1.35 (unch), WBB: 19.79 (-0.02), KIN: 3.45 (-0.23)
